PatientsVille.com Logo


Prostatic Medical Research Studies

Up-to-date List of Prostatic Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Prostatic Medical Research Studies

Rank Status Study
1 Not yet recruiting Prostatic Artery Embolization Versus 532 nm Green Light PVP for Catheterized Patients
Conditions: Benign Prostate Hyperplasia;   Urinary Retention
Interventions: Procedure: Green light PVP;   Procedure: Prostatic artery embolization
Outcome Measures: Ability of the patient to void after removal of the urethral catheter;   Patient subjective satisfaction of both procedures evaluated by the International Prostate Symptom Score (IPSS);   Degree of Prostatic size reduction evaluated by MRI;   Change in peak flow rate (Qmax) and;   Change in post-void residual urine volume (PVR);   Change in prostate specific antigen (PSA)
2 Not yet recruiting Clinical Trial of Prostatic Arterial Embolization Versus a Sham Procedure to Treat Benign Prostatic Hyperplasia
Conditions: Prostatic Hyperplasia, Benign;   Prostatic Hypertrophy, Benign;   Genital Diseases, Male;   Lower Urinary Tract Symptoms;   Prostatic Diseases
Interventions: Procedure: Prostatic Arterial Embolization;   Procedure: Sham procedure
Outcome Measures: Change from baseline in the International Prostate Symptom Score;   Disease specific quality of life question of the International Prostate Symptom Score
3 Recruiting Prostatic Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia (BPH)
Condition: Benign Prostatic Hyperplasia (BPH)
Intervention: Device: Prostate Artery Embolization
Outcome Measures: The Primary Objective is to evaluate the safety of prostate artery embolization (PAE) for the treatment of lower urinary tract symptoms (LUTS) attributed to benign Prostatic hyperplasia (BPH).;   Change in International Prostate Symptom Score (IPSS);   Change in quality of life (QOL) bother question;   Change in benign Prostatic hyperplasia (BPH) impact index;   Change in Qmax (peak and total void volume at each follow‐up visit)
4 Recruiting Configuration of a New Prostate Disease Nomogram Predicting Prostate Biopsy Outcome
Conditions: Prostate Cancer;   Prostatitis;   Benign Prostatic Hyperplasia
Outcome Measures: Incidence of prostate cancer (indolent vs aggressive type);   Incidence of prostatitis (acute vs chronic);   Incidence of nodular hyperplasia (benign Prostatic hyperplasia);   Incidence of patient with synchronous occurrence of prostate diseases (benign Prostatic hyperplasia, prostatitis, prostate cancer)
5 Recruiting Prostate Guided Biopsy Study Evaluating the Diagnostic Performance of Prostate HistoScanning
Condition: Prostate Cancer
Intervention: Device: Prostate HistoScanning
Outcome Measures: Diagnostic performance of prostate HistoScanning (HS) to identify clinically significant PCa using histology outcomes from systematic prostate biopsy (Bx) as reference;   Diagnostic performance of prostate HS to identify PCa using histology outcomes from systematic Bx as reference;   Diagnostic performance of prostate HS to identify clinically significant PCa using a combination of outcomes of both systematic Bx and HS-guided biopsy histology as reference;   Difference in detection rates of clinically significant PCa between systematic and HS-guided biopsy.
6 Recruiting Assessing the Impact of the PVP With Greenlight Laser Using Prostatic MRI and Contrast-enhanced Ultrasound
Condition: Prostatic Hypertrophy, Benign
Intervention: Device: Prostatic photo-vaporization (PVP)
Outcome Measures: Evolution of thickness of the average necrotic area;   Evolution of urinary irritative signs over 12 months;   Evolution of Prostatic volume over 12 months
7 Recruiting Prostate Embolization for Benign Prostatic Hyperplasia
Condition: Benign Prostatic Hyperplasia
Interventions: Procedure: Prostatic Embolization;   Drug: Embosphere® Microspheres
Outcome Measures: Evidence of bladder or rectal ischemic injury;   Detection of bladder or rectal ischemic injury;   Detection of a bladder or rectal ischemic injury;   Improvement in the International Prostate Symptom Score (IPSS);   Improvement in the International Index of Erectile Function (IIEF-5);   Improvement in Uroflowmetry post embolization;   Prostate volume compared to a pre and post embolization;   Serum PSA;   Post-procedure pain;   Procedure time and radiation parameters;   Percentage of prostate tissue devascularized, based on contrast-enhanced MRI.
8 Recruiting Prostatic Artery Embolization vs. Conventional Transurethral Prostatectomy in the Treatment of Benign Prostatic Hyperplasia
Condition: Benign Prostatic Hyperplasia
Interventions: Procedure: Prostatic artery embolization;   Procedure: monopolar transurethral prostatectomy
Outcome Measures: Changes in the International Prostate Symptom Score;   Changes of prostate volume using Magnetic Resonance Imaging;   Changes in bladder diary;   Pre- and postoperative changes in C-reactive Protein, feline serum amyloid A, Interleukin-6 and Interleukin-10
9 Unknown  Imaging for Significant Prostate Cancer Risk Evaluation
Condition: Prostate Cancer
Interventions: Procedure: Prostate HistoScanning;   Procedure: Multi-parametric MRI;   Procedure: Transperineal prostate mapping biopsy;   Procedure: Image guided biopsies
Outcome Measures: Number of men who could avoid repeat biopsy as determined by the Negative predictive value and specificity of mp-MRI for Clinically significant disease.;   Number of men who could avoid repeat biopsy as determined by the negative predictive value and specificity of Prostate HistoScanning for Clinically significant disease.;   Proportion of men correctly identified as having no cancer on Imaging (mp-MRI and Prostate HistoScanning);   Number of men correctly identified by Imaging (mp-MRI and Prostate HistoScanning) to have CLINICALLY SIGNIFICANT disease;   Test- retest reproducibility of Prostate HistoScanning™.;   Proportion of patients with correct disease risk stratification using MRI/US guided biopsies as determined by sensitivity and specificity;   Number of patients with bothersome Lower Urinary tract symptoms following Transperineal Template Mapping biopsy;   Number of patients with worsened erectile function compared to baseline following Transperineal Template Mapping biopsy
10 Recruiting Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia
Condition: Benign Prostatic Hyperplasia
Interventions: Device: Embosphere Microspheres;   Procedure: TURP
Outcome Measures: IPSS Score;   Duration of hospitalization post procedure;   Duration of post procedure catheterization;   Overall and procedure related adverse events;   Safety
11 Recruiting Expressed Prostatic Secretion and Post Massage Urine Biomarkers in Predicting Biopsy Results in Patients Undergoing Prostate Biopsy
Conditions: Conditions Influencing Health Status;   Healthy;   Prostate Cancer
Interventions: Other: laboratory biomarker analysis;   Procedure: transrectal prostate biopsy
Outcome Measures: Determine whether EPS or PMU is a better predictor of prostate cancer biopsy results by measuring and comparing the number of Prostatic cells collected;   Comparison of the area under the curve (AUC) for sensitivity and specificity of TMPRSS2:ERG single and double fusion assays and biopsy results in patients with prostate cancer, undergoing prostate screening;   Comparison of the AUC for sensitivity and specificity of the methylation status of the androgen receptor (AR) and GSTP1 promoter, APC and RARB and biopsy results in men with prostate cancer, undergoing prostate screening;   Determine by comparison of AUCs which combination of molecular markers offers the greatest improvements in our ability to predict biopsy outcome over current baseline predictors (serum PSA and DRE);   Comparison through the AUCs of the association of EPS or PMU TMPRSS2:ERG fusion assay and methylation of the GSTP1 promoter, APC, RARB assays and PCA3 to the results of TRUSP and biopsy in men with unknown prostate cancer status
12 Recruiting High Dose Rate Prostate Brachytherapy: Dose Escalation to Dominant Intra-Prostatic Nodule
Condition: Prostate Cancer
Intervention: Radiation: HDR interstitial brachytherapy
Outcome Measures: Feasibility of delivery of a higher than prescription dose to the dominant intra-Prostatic nodule as defined on diffusion contrast-enhanced endo-rectal MRI, while respecting tolerance doses of adjacent normal organs.;   Acute toxicity compared to a cohort of 25 patients treated to standard dose;   Efficacy will be assessed by repeat DCE MRI at 12 months and TRUS-guided prostate biopsy at 30 months.
13 Unknown  Prostate Cancer - Qatar
Condition: Prostate Cancer
Outcome Measures: Identification of single nucleotide polymorphisms (SNPs) in genes associated with prostate cancer in the Qatari population.;   Use of gene expression profiles to develop molecular signatures of prostate cancer that are associated with clinical/pathological phenotypes (e.g., tumor grade, histology, disease stage, responsiveness to therapy)
14 Recruiting Clinical Trial to Evaluate the Efficacy and Safety of the Transarterial Supraselective Embolization of the Prostate to Treat the Urinary Symptoms.
Conditions: Transurethral Resection of Prostate;   Artery Embolization;   Benign Prostatic Hyperplasia;   Lower Urinary Tract Symptoms
Interventions: Procedure: Transarterial Supraselective Embolization of the prostate;   Procedure: Transurethral Resection of the prostate
Outcome Measures: Maximum urinary flow (Qmax);   International Prostate Symptom Score (IPSS) measured before and after the intervention;   Reduction in prostate volume;   Sexual function
15 Not yet recruiting Results of Selective Prostatic Arterial Embolization in Patients With Indwelling Urinary Catheter Due to Benign Prostatic Hyperplasia Refractory to Medical Treatment.
Condition: Benign Prostatic Hyperplasia
Intervention: Device: Prostatic arterial embolization using BeadBlock (Terumo)
Outcome Measures: Procedural Success;   success of the procedure : ability to urinate after their catheter
16 Unknown  MRI in Diagnosing Prostate Cancer
Condition: Prostate Cancer
Interventions: Other: biologic sample preservation procedure;   Other: laboratory biomarker analysis;   Other: study of socioeconomic and demographic variables;   Procedure: diffusion-weighted magnetic resonance imaging;   Procedure: dynamic contrast-enhanced magnetic resonance imaging;   Procedure: multiparametric magnetic resonance imaging;   Procedure: quality-of-life assessment;   Procedure: transperineal prostate biopsy;   Procedure: transrectal prostate biopsy;   Procedure: ultrasound-guided prostate biopsy
Outcome Measures: Safety of multiparametric magnetic resonance imaging (MP-MRI);   Recruitment;   Proportion of men who could safely avoid biopsy as determined by specificity and negative predictive values;   Proportion of men correctly identified by MP-MRI to have clinically significant prostate cancer as determined by sensitivity and positive predictive values;   Proportion of men who could safely avoid biopsy;   Proportion of men testing positive on MP-MRI;   Performance characteristics of TRUS versus template prostate mapping (TPM);   Evaluation of the optimal combination of MP-MRI functional parameters;   Intra-observer variability in the reporting of MP-MRI;   Evaluation of socio-demographic, clinical, imaging and radiological variables in relation to the detection of clinically significant prostate cancer;   Health-related quality of life using the EQ-5D questionnaire;   Resource use and costs for further economic evaluation;   Translational research
17 Recruiting Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy
Condition: Prostate Cancer
Intervention: Drug: Degarelix
Outcome Measures: prostate volume reduction;   testosterone recovery
18 Not yet recruiting MRI Before Biopsy in Diagnosing Patients With Prostate Cancer
Condition: Prostate Cancer
Interventions: Device: magnetic resonance imaging;   Procedure: prostate biopsy
Outcome Measures: Increased detection of clinically significant prostate cancer;   Detection of clinically significant prostate cancer using 3D T2 SPACE;   Detection of clinically significant prostate cancer using 3D T2 HASTE
19 Recruiting Efficacy Study of HoLEP and TURP on LUTS Secondary to BPH
Conditions: Lower Urinary Tract Symptoms;   Benign Prostatic Hyperplasia
Interventions: Procedure: Transurethral resection of the prostate;   Procedure: Holmium Laser Enucleation of the Prostate
Outcome Measures: The changes of International Prostatic Symptom Scores (IPSS) from baseline to 6 months after operation;   The changes of Quality of Life (QoL) parameters;   The changes of IPSS and QoL parameters;   The changes of Uroflowmetry (UFM) and Postvoid residual urine(PVR) parameters;   Postoperative hospital stay days and postoperative catheterization days;   The changes of the hemoglobin and the serum sodium;   Operative time and Resected tissue weight;   The changes of ICS male questionnaire (short form) parameters;   The changes of international index of erectile function (IIEF)-15 parameters;   The changes of Patient perception of treatment benefit questionnaire (PPTB) parameters;   The changes of voiding frequencies and urgency parameters in Frequency volume chart;   Ejaculation parameter;   Complications
20 Unknown  Prostate Cancer Antigen 3 (PCA-3) Gene Project
Conditions: Prostate Cancer;   Benign Prostatic Hypertrophy
Intervention: Biological: Taking of urines
Outcome Measures: To evaluate the specificity and the sensibility of PCA-3 marker in patients treated for Prostatic pathology (benign or malign).;   To analyse expression of several other Prostatic markers (genes coding for androgen receptor and steroid alpha-reductase type 1 and 2)in the aim to improve the prostate cancer diagnosis specificity.

These studies may lead to new treatments and are adding insight into Prostatic etiology and treatment.

A major focus of Prostatic research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Prostatic